COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS
Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
1 - 24 . (canceled)
25 . A method for inducing an immune response in a subject against three or more dengue virus serotypes, the method comprising:
administering a first immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising at least one non-chimeric live, attenuated dengue-2 virus and at least one dengue-dengue chimera having a live, attenuated dengue-2 virus backbone; and
administering a second immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising at least one non-chimeric live, attenuated dengue-2 virus and at least one dengue-dengue chimera having a live, attenuated dengue-2 virus backbone;
wherein the first immunogenic composition and the second immunogenic composition are administered at the same anatomical location on the same day to the subject; and
inducing an immune response in the subject against the three or more dengue virus serotypes.
26 . The method of claim 25 , wherein the first immunogenic composition and the second immunogenic composition comprise different compositions.
27 . (canceled)
28 . The method of claim 25 , wherein the first immunogenic composition comprises three or four dengue virus serotypes at predetermined ratios.
29 . The method of claim 25 , wherein the first immunogenic composition comprises a tetravalent formulation of all four dengue virus serotypes.
30 - 31 . (canceled)
32 . The method of claim 25 , wherein the at least one dengue-dengue chimera of a live, attenuated dengue virus comprises non-structural proteins from at least one dengue virus serotype and pre-membrane and envelope proteins from at least a second dengue virus serotype.
33 . The method of claim 25 , wherein the at least one dengue-dengue chimera of a live, attenuated dengue virus is selected from dengue-2/dengue-1, dengue-2/dengue-3, and dengue-2/dengue-4, wherein dengue-2 is the backbone and dengue-1, dengue-3 or dengue-4 contribute pre-membrane and envelope proteins.
34 . The method of claim 25 , wherein the serotype, dengue-4, is present in at least the first composition at a concentration about 1.5 times greater than any other dengue serotype.
35 . The method of claim 34 , wherein dengue-4 is present in at least the first composition and is at least about 10 times greater than dengue-2.
36 . The method of claim 25 , further comprising administering to the subject at least one additional immunogenic agent.
37 . The method of claim 25 , wherein the first immunogenic composition and the second immunogenic composition are administered to the subject subcutaneously.
38 . The method of claim 25 , further comprising administering at least one additional booster administration of a formulation of a live, attenuated dengue vaccine after administration of the compositions of claim 25 .
39 . The method of claim 38 , wherein the at least one additional booster administration is administered subcutaneously to the subject after administration of the compositions of claim 25 .
40 . The method of claim 25 , wherein at least one additional subcutaneous administration of the first immunogenic composition or the second immunogenic composition is administered to the subject after the initial administration.
41 . A method for inducing an immune response in a subject against three or more dengue virus serotypes, the method comprising:
administering a first immunogenic composition of a monovalent live, attenuated dengue virus;
administering a second immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising at least one non-chimeric live, attenuated dengue-2 virus and at least one dengue-dengue chimera having a live, attenuated dengue-2 virus backbone; and;
wherein the first immunogenic composition and the second immunogenic composition are administered at two or more anatomical locations consecutively on the same day to the subject; and
inducing an immune response in the subject against the three or more dengue virus serotypes.
42 - 43 . (canceled)
44 . The method of claim 41 , wherein the second immunogenic composition comprises at least three dengue virus serotypes at predetermined ratios.
45 . The method of claim 41 , wherein the second immunogenic composition comprises a tetravalent formulation of all four dengue virus serotypes.
46 . The method of claim 41 , wherein the two or more anatomical locations comprise different anatomical locations on different body parts of the subject.
47 . The method of claim 41 , wherein the two or more anatomical locations comprise different anatomical locations on the same body part of the subject.
48 . The method of claim 41 , wherein the at least one dengue-dengue chimera of a live, attenuated dengue virus comprises non-structural proteins from at least one dengue virus serotype and pre-membrane and envelope proteins from at least a second dengue virus serotype.
49 . The method of claim 41 , wherein the at least one dengue-dengue chimera of a live, attenuated dengue virus is selected from dengue-2/dengue-1, dengue-2/dengue-3, and dengue-2/dengue-4, wherein dengue-2 is the backbone and dengue-1, dengue-3 or dengue-4 contribute pre-membrane and envelope proteins.
50 . The method of claim 41 , wherein the serotype, dengue-4, is present in at least the second composition at a concentration about 1.5 times greater than any other dengue serotype.
51 . The method of claim 50 , wherein dengue-4 is present in at least the second composition and is at least about 10 times greater than dengue-2.
52 . The method of claim 41 , further comprising administering to the subject at least one additional immunogenic agent.
53 . The method of claim 41 , wherein the first immunogenic composition and the second immunogenic composition are administered to the subject subcutaneously.
54 . The method of claim 41 , further comprising administering at least one additional booster administration of a formulation of a live, attenuated dengue vaccine after administration of the compositions of claim 1 .
55 . The method of claim 54 , wherein the at least one additional booster administration is administered subcutaneously to the subject after administration of the compositions of claim 1 .
56 . (canceled)
57 . A vaccine kit for carrying out the method of claim 41 , the kit comprising:
an immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising at least one non-chimeric live, attenuated dengue virus and at least one dengue-dengue chimera of a live, attenuated dengue virus; and
an immunogenic composition of one live, attenuated dengue virus, the composition comprising one non-chimeric live, attenuated dengue virus or one dengue-dengue chimera of a live, attenuated dengue virus;
at least two devices capable of administering the compositions to a subject.
58 . The kit of claim 57 , wherein the immunogenic compositions comprise different formulations.
59 . The kit of claim 57 , further comprising at least one immunogenic agent.
60 . The kit of claim 57 , wherein the immunogenic composition of three or more live, attenuated dengue viruses comprises a tetravalent composition of all four dengue virus serotypes.
61 . The method of claim 25 , wherein the first immunogenic composition and the second immunogenic composition comprise the same composition.
62 . The method of claim 41 , wherein the monovalent live, attenuated dengue virus comprises dengue serotype 4.